• Endo Pharmaceuticals Solutions, Inc. v. Custopharm Inc. (Fed. Cir. 2018)
    in: Federal Circuit, obviousness  | 

    Endo Pharmaceuticals Solutions, Inc. v. Custopharm Inc. (Fed. Cir. 2018)

    By Donald Zuhn — Last month, in Endo Pharmaceuticals Solutions, Inc. v. Custopharm Inc., the Federal Circuit affirmed a decision by the U.S. District Court for the District of Delaware finding that Defendant-Appellant Custopharm Inc. had not proven that claim 2 of U.S. Patent No. 7,718,640 or claim 18 of U.S. Patent No. 8,338,395 were invalid as obvious under 35 U.S.C. § 103. The ‘640 and ‘395 patents are owned by Plaintiffs-Appellees Bayer Intellectual Property GmbH and Bayer Pharma AG. Seeking approval to market a generic version of Aveed®, a long-acting injectable testosterone replacement therapy for men suffering from physiologically…

  • Conference & CLE Calendar
    in: Conferences & CLE's  | 

    Conference & CLE Calendar

    August 21, 2018 – “Navigating the Patent Prosecution Highway and Other Accelerated Filing Options — Evaluating the Different Options, Weighing the Benefits and Risks, Obtaining Patent Protection” (Strafford) – 1:00 to 2:30 pm (EDT) August 21, 2018 – “…

  • この他に
    in:  | 

    この他に

                            目次はこちら

    この他に

    (ANOTHER/OTHER)
    $$ In another known uplink receiving antenna arrangement for a cellular mobile communications system, gain is improved by t…